News & Analysis on Clinical Trial Services & Contract Research And Development
Australia's Benitec, a specialist in gene silencing technologies based on RNA interference (RNAi), has broadened its patent estate by licensing a technology from Stanford University in the US that could overcome the problems in delivering these agents...
Thermo Electron has launched a new elemental benchtop analyser for use by researchers and quality control scientists in the petrochemical, plastics and high-grade chemical industries.
Asthma research company Synairgen, has announced plans to seek a listing on London's Alternative Investment Market (AIM) to raise funds for the research and development of chronic bronchitis (COPD) and asthma.
ESA has introduced what it claims is the first true universal detector for use with high performance liquid chromatography (HPLC), a based on a technology called CAD (charged aserosol detector).
Serologicals has completed its acquisition of Upstate Group, acquiring the privately held company for $205 million (€166m) in cash ($102.5m) and stock.
The first system to automate gel casting to user-defined gradients during 2D electrophoresis has been launched worldwide by NextGen Sciences, which believe this technology will increase reproducability and enhance the resolution of protein separations.
Leading instrument company Beckman Coulter has launched new software for its Cytomics FC 500 MPL flow cytometer which it enables users to automate instrument set-up and data acquisition, which could help the process of identifying new drug targets.
Integra Biosciences has updated the traditional design of the Bunsen burner by coming up with a new version, which incorporates a unique triple safety system and a self-igniting system that does away with lighters or matches.
UK-based Avecia has been awarded a $50.7 million (€41m) contract by the US government for the development of a recombinant plague vaccine. The contract provides funds for pilot lot manufacture, release, testing and initial human clinical trials over...